Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VKTX Viking Therapeutics, Inc.

盘前交易 04-23 04:51:05 EDT

63.85

+0.43

+0.68%

最高64.94	最低62.30	成交量156.24万
今开64.13	昨收63.42	日振幅4.16%
总市值70.37亿	流通市值65.77亿	总股本1.10亿
成交额9,974万	换手率1.52%	流通股本1.03亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"VKTX","market":"US","secType":"STK","nameCN":"Viking Therapeutics, Inc.","latestPrice":63.85,"timestamp":1713816000000,"preClose":63.42,"halted":0,"volume":1562386,"delay":0,"floatShares":103000000,"shares":110217994,"eps":-0.910415,"marketStatus":"盘前交易","marketStatusCode":1,"change":0.43,"latestTime":"04-23 04:51:05 EDT","open":64.13,"high":64.94,"low":62.3,"amount":99744425.24074,"amplitude":0.041627,"askPrice":70,"askSize":100,"bidPrice":64,"bidSize":227,"shortable":3,"etf":0,"ttmEps":-0.910415,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1713879000000},"adr":0,"listingDate":1430280000000,"adjPreClose":63.85,"adrRate":0,"postHourTrading":{"tag":"盘后","latestPrice":64.47,"preClose":63.85,"latestTime":"19:58 EDT","volume":40757,"amount":2603315.9945,"timestamp":1713830281675},"volumeRatio":0.6694687711073978},"requestUrl":"/m/hq/s/VKTX","defaultTab":"news","newsList":[{"id":"2429771900","title":"Viking Therapeutics Inc    预计每股亏损 28 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2429771900","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2429771900?lang=zh_cn&edition=full","pubTime":"2024-04-23 07:02","pubTimestamp":1713826938,"startTime":"0","endTime":"0","summary":"   * Viking Therapeutics Inc    将于4月24日公布截至2024年3月31日的财报，预计季度收入将保持不变。*    * LSEG分析师对Viking Therapeutics Inc的平均预期是每股亏损28美分。* 华尔街对 Viking Therapeutics Inc 的 12 个月目标价中位数为 115.00 美元，高于其上次收盘价 63.85 美元。4月22日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428790561","title":"减肥药开发商 Metsera 获得 2.9 亿美元融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2428790561","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2428790561?lang=zh_cn&edition=full","pubTime":"2024-04-18 19:09","pubTimestamp":1713438543,"startTime":"0","endTime":"0","summary":"Metsera公司由风险投资公司ARCH Venture和投资公司Population Health Partners于2022年成立，目前正在开发基于GLP-1机制和其他生物靶点的治疗肥胖症的注射和口服药物。Meanwell 说，Metsera 的 2.9 亿美元融资是迄今为止从领先的医疗保健投资者银团筹集到的资金总额，包括种子轮和 A 轮融资。Meanwell 拒绝就融资的估值发表评论。Meanwell曾担任The Medicines Company首席执行官近20年，该公司于2019年被瑞士制药商诺华  以97亿美元收购， 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2426111794","title":"Viking Therapeutics, Inc.盘中异动 临近午盘股价大跌5.02%报72.07美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2426111794","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426111794?lang=zh_cn&edition=full","pubTime":"2024-04-09 23:35","pubTimestamp":1712676945,"startTime":"0","endTime":"0","summary":"北京时间2024年04月09日23时35分，Viking Therapeutics, Inc.股票出现波动，股价急速下挫5.02%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.46%。其相关个股中，Acrivon Therapeutics, Inc.、Revolution Medicines Inc C/Wts 17/12/2026 、Syros Pharmaceuticals, Inc.涨幅较大，Mymd Pharmaceuticals, Inc.、Biophytis、Acrivon Therapeutics, Inc.较为活跃，换手率分别为459.92%、105.59%、82.91%，振幅较大的相关个股有Mymd Pharmaceuticals, Inc.、Biophytis、Cadrenal Therapeutics, Inc.，振幅分别为45.14%、40.61%、39.14%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040923354587e7ee92&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040923354587e7ee92&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425992595","title":"Viking Therapeutics, Inc.盘中异动 急速上涨5.05%报77.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2425992595","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2425992595?lang=zh_cn&edition=full","pubTime":"2024-04-06 01:19","pubTimestamp":1712337543,"startTime":"0","endTime":"0","summary":"北京时间2024年04月06日01时19分，Viking Therapeutics, Inc.股票出现波动，股价大幅拉升5.05%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.26%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240406011903791edc2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240406011903791edc2d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425349231","title":"Viking Therapeutics, Inc.盘中异动 下午盘股价大跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2425349231","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2425349231?lang=zh_cn&edition=full","pubTime":"2024-04-05 02:15","pubTimestamp":1712254559,"startTime":"0","endTime":"0","summary":"北京时间2024年04月05日02时15分，Viking Therapeutics, Inc.股票出现异动，股价急速跳水5.07%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.42%。其相关个股中，Candel Therapeutics, Inc.、Tc Biopharm  Plc C/Wts 10/02/2028 、Tc Biopharm  Plc涨幅较大，Tc Biopharm  Plc、Candel Therapeutics, Inc.、Effector Therapeutics, Inc.较为活跃，换手率分别为3482.49%、276.26%、216.74%，振幅较大的相关个股有Nls Pharmaceutics Ltd C/Wts 02/02/2026、Candel Therapeutics, Inc.、Tc Biopharm  Plc，振幅分别为133.46%、116.07%、111.54%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404050215597a510884&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404050215597a510884&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424232043","title":"Viking Therapeutics, Inc.盘中异动 早盘股价大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2424232043","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2424232043?lang=zh_cn&edition=full","pubTime":"2024-04-02 21:40","pubTimestamp":1712065201,"startTime":"0","endTime":"0","summary":"北京时间2024年04月02日21时40分，Viking Therapeutics, Inc.股票出现波动，股价大幅下挫5.04%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.33%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。消息层面，截至21时40分，《维京治疗来势汹汹，但撼动礼来、诺和诺德江湖地位仍为时尚早》资讯为影响Viking Therapeutics, Inc.的重要信息。智通财经APP了解到，目前，维京治疗Viking Therapeutics的 VK2735 已成为 GLP-1 药物市场的有力竞争者，在临床研究中取得了良好的减肥效果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404022140027a50b625&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404022140027a50b625&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"1134994137","title":"维京治疗来势汹汹，但想撼动礼来、诺和诺德仍为时尚早","url":"https://stock-news.laohu8.com/highlight/detail?id=1134994137","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/1134994137?lang=zh_cn&edition=full","pubTime":"2024-04-01 18:48","pubTimestamp":1711968535,"startTime":"0","endTime":"0","summary":"制药和生物技术行业争相开发GLP-1药物，维京治疗成为最有力竞争者。","market":"us","thumbnail":"https://static.tigerbbs.com/13979f39d2d97a07bd73c546f6da4b71","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/13979f39d2d97a07bd73c546f6da4b71"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1097148.html","is_publish_highlight":true,"gpt_icon":1},{"id":"2423439733","title":"减肥药试验成功潜力巨大！这只小盘股有望起飞","url":"https://stock-news.laohu8.com/highlight/detail?id=2423439733","media":"金十数据","top":-1,"share":"https://www.laohu8.com/m/news/2423439733?lang=zh_cn&edition=full","pubTime":"2024-03-29 15:43","pubTimestamp":1711698214,"startTime":"0","endTime":"0","summary":"TERN是一家备受关注的小盘股公司，他们正在进行一项引人瞩目的肥胖症治疗药物试验。","market":"hk","thumbnail":"https://cdn-news.jin10.com/c40c0b04-c780-4fae-8a17-73b8cb5cb986.png/lite","type":0,"news_type":0,"thumbnails":["https://cdn-news.jin10.com/c40c0b04-c780-4fae-8a17-73b8cb5cb986.png/lite"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://xnews.jin10.com/webapp/details.html?id=135429&type=news&data_type=0","is_publish_highlight":false,"gpt_icon":0},{"id":"2422751997","title":"Viking Therapeutics, Inc.盘中异动 早盘急速拉升5.01%报84.88美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422751997","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422751997?lang=zh_cn&edition=full","pubTime":"2024-03-27 21:33","pubTimestamp":1711546404,"startTime":"0","endTime":"0","summary":"北京时间2024年03月27日21时33分，Viking Therapeutics, Inc.股票出现异动，股价快速上涨5.01%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.30%。其相关个股中，Ibio, Inc.、Lixte Biotechnology Holdings, Inc.、Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 涨幅较大，Ibio, Inc.、Lixte Biotechnology Holdings, Inc.、Hoth Therapeutics, Inc.较为活跃，换手率分别为951.03%、445.08%、50.05%，振幅较大的相关个股有Ibio, Inc.、Apollomics Inc C/Wts 01/04/2028 、Lixte Biotechnology Holdings, Inc.，振幅分别为41.74%、27.59%、25.94%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240327213325861e1acd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240327213325861e1acd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422987585","title":"港股概念追踪 |Viking(VKTX.US)创新口服减肥疗法临床结果积极 减肥药受关注（附概念股）","url":"https://stock-news.laohu8.com/highlight/detail?id=2422987585","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422987585?lang=zh_cn&edition=full","pubTime":"2024-03-27 10:42","pubTimestamp":1711507367,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月26日，Viking Therapeutics公司宣布，该公司的口服疗法VK2735在治疗肥胖症的1期临床试验中获得积极结果，接受最高剂量治疗的参与者在28天后体重减少5.3%。根据弗若斯特沙利文的报告，全球减肥药物市场规模从2016 年的18亿美元增长到2020年的26亿美元，年复合增长率为9.0%。值得一提是，目前体重管理适应症的相关药物在国内尚未批准上市，联邦制药是国内首家获得该生物类似物临床批件的企业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032712273387ba9fb0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032712273387ba9fb0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422603210","title":"4周体重下降近10斤！Viking(VKTX.US)创新口服减肥疗法临床结果积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2422603210","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422603210?lang=zh_cn&edition=full","pubTime":"2024-03-27 08:48","pubTimestamp":1711500536,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月26日，Viking Therapeutics公司宣布，该公司的口服疗法VK2735在治疗肥胖症的1期临床试验中获得积极结果，接受最高剂量治疗的参与者在28天后体重减少5.3%。这项为期28天的剂量递增研究结果突显了口服VK2735治疗的积极临床活性。口服VK2735显示出良好的安全性和耐受性。Viking还计划在2024年下半年，针对肥胖患者启动口服VK2735的2期试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1093079.html","is_publish_highlight":false,"gpt_icon":0},{"id":"1110387722","title":"昨夜今晨 | 官宣利好，“减肥药新贵”Viking飙升近17%；英伟达尾盘跳水，特斯拉逆市涨近3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1110387722","media":"老虎资讯综合","top":-1,"share":"https://www.laohu8.com/m/news/1110387722?lang=zh_cn&edition=full","pubTime":"2024-03-27 07:34","pubTimestamp":1711496082,"startTime":"0","endTime":"0","summary":"“减肥药新贵”Viking飙涨逾17%隔夜美股三大股指尾盘跳水，截至收盘，标普500跌0.28%，报5203.58点；纳斯达克指数跌0.42%，报16315.7点；道琼斯工业指数跌0.08%，报39282.33点。超级科技巨头多数走弱，英伟达冲高乏力尾盘跳水跌超2%，META跌超1%，苹果、微软、亚马逊微跌，特斯拉逆市涨近3%。截至发稿，特斯拉的全自动驾驶功能售价为12000美元。叠加商讨意大利建厂的消息影响，特斯拉周二一度涨超6%，收盘时涨幅","market":"us","thumbnail":"https://static.tigerbbs.com/b23574aac95526c9e5c62ebc8dd25130","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/b23574aac95526c9e5c62ebc8dd25130"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"gpt_icon":1},{"id":"2422643190","title":"Viking Therapeutics(VKTX)涨26% VK2735肥胖药早期研究报积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2422643190","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2422643190?lang=zh_cn&edition=full","pubTime":"2024-03-26 23:40","pubTimestamp":1711467601,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物制药公司Viking Therapeutics(VKTX)股价抽升，截至发稿，涨26%，报87.13美元。公司报告了对其拟议的VK2735肥胖药物口服制剂的早期研究的积极结果。VK2735口服制剂的1期研究显示，经安慰剂调整后的28天后平均体重减轻3.3%，并补充说，该药物安全且耐受性良好，与胃肠道相关的不良事件发生率低。与目前火爆全球的GLP-1药物类似但又不同的是，VK2735不仅针对胰高血糖素样肽1(GLP-1)，同样还针对葡萄糖依赖性胰岛素促泌肽(GIP)受体，是一种双重激动剂。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/ZTViYmJjYTk5MWJmNjYzNjE2ODI2MDU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZTViYmJjYTk5MWJmNjYzNjE2ODI2MDU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"274346","is_publish_highlight":false,"gpt_icon":0},{"id":"2422613198","title":"Viking Therapeutics, Inc.股价上涨16.77% 市值涨14.62亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422613198","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422613198?lang=zh_cn&edition=full","pubTime":"2024-03-26 21:31","pubTimestamp":1711459909,"startTime":"0","endTime":"0","summary":"北京时间2024年03月26日21时31分，Viking Therapeutics, Inc.股票出现波动，股价急速拉升16.77%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.41%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403262131498b65772d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403262131498b65772d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422492618","title":"“减肥药新贵”Viking的口服减肥药最新试验结果积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2422492618","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422492618?lang=zh_cn&edition=full","pubTime":"2024-03-26 21:10","pubTimestamp":1711458642,"startTime":"0","endTime":"0","summary":"到2030年，全球抗肥胖药物市场的年销售额可能会增长到1000亿美元左右。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1092768.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422669308","title":"BUZZ-维京药物在早期试验中被证明可减轻体重；股价上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2422669308","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2422669308?lang=zh_cn&edition=full","pubTime":"2024-03-26 19:21","pubTimestamp":1711452079,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    3月26日 - ** Viking Therapeutics   股价盘前上涨约11.3%至77美元** 该公司称 (link) 其药物 VK2735 在早期试验中显示，与安慰剂相比，平均体重减轻达 3.3** 公司计划根据早期数据，在今年晚些时候启动一项中期试验** 截至上次收盘，公司股价在过去 12 个月中上涨了七倍多","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422951736","title":"更新版 1-Viking Therapeutics 的实验性药片在小型研究中有助于减轻体重","url":"https://stock-news.laohu8.com/highlight/detail?id=2422951736","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2422951736?lang=zh_cn&edition=full","pubTime":"2024-03-26 19:18","pubTimestamp":1711451928,"startTime":"0","endTime":"0","summary":"     路透社3月26日 - Viking Therapeutics   周二表示，其实验性药片有助于减轻体重，而且在早期研究中被证明是安全的，这使该公司股价在盘前交易中上涨了10%。该公司表示，根据早期研究数据，计划在今年晚些时候启动第二阶段试验。Viking Therapeutics 公司称，该研究观察到，在 28 天内，7 名患者的平均体重减轻了 3.3%，如果与安慰剂比例进行调整的话。该公司上个月报告了一项中期研究的数据，其实验性注射药物VK2735帮助肥胖症患者平均减轻了近15%的体重。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422841693","title":"Viking Therapeutics 公司称其实验性药片在早期研究中减轻了体重","url":"https://stock-news.laohu8.com/highlight/detail?id=2422841693","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2422841693?lang=zh_cn&edition=full","pubTime":"2024-03-26 19:09","pubTimestamp":1711451359,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社3月26日 - Viking Therapeutics   周二称，在一项早期试验中，该公司的实验性片剂有助于减轻患者的体重，而且在研究中被证明是安全有效的。该公司表示，计划根据早期数据在今年晚些时候启动第二阶段试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422487715","title":"Viking Therapeutics, Inc.盘中异动 急速拉升5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422487715","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422487715?lang=zh_cn&edition=full","pubTime":"2024-03-25 21:52","pubTimestamp":1711374736,"startTime":"0","endTime":"0","summary":"北京时间2024年03月25日21时52分，Viking Therapeutics, Inc.股票出现波动，股价急速拉升5.06%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.07%。其相关个股中，Landos Biopharma, Inc.、Xtl生物制药、Altamira Therapeutics Ltd.涨幅较大，Altamira Therapeutics Ltd.、Xtl生物制药、Salarius Pharmaceuticals, Inc.较为活跃，换手率分别为1869.98%、72.66%、57.49%，振幅较大的相关个股有Xtl生物制药、Altamira Therapeutics Ltd.、Brainstorm Cell Therapeutics Inc.，振幅分别为71.37%、45.67%、26.61%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240325215216861e0e00&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240325215216861e0e00&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vikingtherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0463},{"period":"1month","weight":-0.082},{"period":"3month","weight":1.7439},{"period":"6month","weight":4.9841},{"period":"1year","weight":2.0104},{"period":"ytd","weight":2.431}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0412},{"period":"3month","weight":0.0306},{"period":"6month","weight":0.1968},{"period":"1year","weight":0.2123},{"period":"ytd","weight":0.0514}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Viking Therapeutics, Inc.于2012年9月24号在特拉华州成立。该公司是一个临床阶段的生物制药公司，致力于开发新的，第一类或最好的新陈代谢和内分泌失调类疗法。该公司拥有全球独家权利基于许可的配体小分子组合在五个候选药物在临床试验或临床前研究。公司的主导临床程序是VK0612，它是进入2b期临床试验为2型全球最大的健康挑战之一的治疗糖尿病疾病口服药物，它在同药物中排列第一。公司的第二临床程序vk5211，可把口服的候选药物送入第二阶段临床试验治疗一种复杂的疾病特点的不受控制的肌肉质量下降癌症恶病。VK5211是一种非甾体选择性雄激素受体调节剂，或SARM。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.031825},{"month":2,"riseRate":0.555556,"avgChangeRate":0.264573},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.020024},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.021837},{"month":5,"riseRate":0.333333,"avgChangeRate":0.129034},{"month":6,"riseRate":0.444444,"avgChangeRate":-0.009265},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.014001},{"month":8,"riseRate":0.444444,"avgChangeRate":0.019922},{"month":9,"riseRate":0.333333,"avgChangeRate":0.070513},{"month":10,"riseRate":0.222222,"avgChangeRate":-0.002105},{"month":11,"riseRate":0.555556,"avgChangeRate":0.0115},{"month":12,"riseRate":0.666667,"avgChangeRate":0.206888}],"exchange":"NASDAQ","name":"Viking Therapeutics, Inc.","nameEN":"Viking Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Viking Therapeutics, Inc.(VKTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Viking Therapeutics, Inc.,VKTX,Viking Therapeutics, Inc.股票,Viking Therapeutics, Inc.股票老虎,Viking Therapeutics, Inc.股票老虎国际,Viking Therapeutics, Inc.行情,Viking Therapeutics, Inc.股票行情,Viking Therapeutics, Inc.股价,Viking Therapeutics, Inc.股市,Viking Therapeutics, Inc.股票价格,Viking Therapeutics, Inc.股票交易,Viking Therapeutics, Inc.股票购买,Viking Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Viking Therapeutics, Inc.(VKTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况